Peer-reviewed veterinary case report
Etoposide and piroxicam effects on dog bone cancer cells
By Ong, S M et al.·Published in Veterinary journal (London, England : 1997)·2016·Graduate School of Agricultural and Life Sciences, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effects of etoposide alone and in combination with piroxicam on canine osteosarcoma cell lines.
- Species:
- dog
Plain-English summary
A study looked at how well etoposide, a cancer drug, works alone and with piroxicam, a pain medication, against osteosarcoma (a common bone cancer) in dogs. The researchers found that etoposide alone was effective in slowing down cancer cell growth, but when combined with piroxicam, it worked even better. This combination treatment showed promise in killing cancer cells more effectively, suggesting it could be a potential new option for treating dogs with osteosarcoma. More research is needed to confirm these findings and explore this treatment further.
People also search for: dog osteosarcoma treatment · etoposide for dogs cancer · piroxicam for dog pain
Abstract
Osteosarcoma (OSA) is the most common primary bone tumour in dogs. The poor survival rate in dogs with OSA highlights the need for new therapeutic approaches. This study evaluated the cytotoxic effects of etoposide, alone and in combination with piroxicam, on canine OSA cell cultures. Etoposide alone significantly suppressed cell growth and viability, whereas etoposide in combination with piroxicam exhibited concentration dependent cytotoxicity. The anti-proliferative effect was a result of inactivity of the Cdc2-cyclin B1 complex, which correlated with an increase in the G/M fraction. This subsequently activated the apoptosis cascade, as indicated by elevated apoptosis levels and up-regulation of poly (ADP-ribose) polymerase proteolytic cleavage. Down-regulation of survivin expression induced by the combination treatment may have contributed to the enhanced cytotoxicity. The results of this study suggest that further investigation of etoposide and piroxicam as a therapeutic combination for canine OSA is warranted.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27938709/